Patient characteristics at the time of starting first choice 2G-TKI and 4-year probabilities of OS and EFS
| Variable . | n . | Survival . | Significance . | EFS . | Significance . |
|---|---|---|---|---|---|
| Age, y* | |||||
| > 50 | 50 | 68.5% | 27.8% | ||
| ≤ 50 | 69 | 91.6% | P = .04 | 41.1% | P = .08 |
| Sex | |||||
| Male | 65 | 83.9% | 31.6% | ||
| Female | 54 | 78.2% | P = .8 | 39.9% | P = .6 |
| Sokal risk group | |||||
| Low | 30 | 100% | 45.5% | ||
| Intermediate | 48 | 83.9% | 28.6% | ||
| High | 41 | 66.5% | P = .03 | 34.7% | P = .7 |
| Status at the onset of imatinib therapy | |||||
| Newly diagnosed CP patients | 60 | 77.8% | 30.7% | ||
| Late CP | 59 | 84.6% | P = .4 | 39.1% | P = .3 |
| Additional cytogenetic abnormalities | |||||
| No | 84 | 85.2% | 41.8% | ||
| Yes | 35 | 75% | P = .2 | 21.3% | P = .07 |
| Time from diagnosis to 2G-TKIs, y† | |||||
| ≤ 6 | 59 | 81.1% | 31.8% | ||
| > 6 | 60 | 82.2% | P = .7 | 38.3% | P = .3 |
| Hematologic resistance to imatinib | |||||
| Yes | 31 | 76.7% | 22.5% | ||
| No | 88 | 84.5% | P = .4 | 40.5% | P = .01 |
| Primary cytogenetic resistance to imatinib | |||||
| Yes | 37 | 70.5% | 13.5% | ||
| No | 82 | 87.9% | P = .03 | 46.7% | P = .001 |
| Need of dose reduction of imatinib (< 400 mg twice daily) | |||||
| Yes | 43 | 97.1% | 50.4% | ||
| No | 76 | 77.3% | P = .06 | 30.2% | P = .08 |
| KD mutation | |||||
| Yes | 26 | 89.3% | 39.0% | ||
| No | 93 | 80.2% | P = .2 | 32.9% | P = .9 |
| Variable . | n . | Survival . | Significance . | EFS . | Significance . |
|---|---|---|---|---|---|
| Age, y* | |||||
| > 50 | 50 | 68.5% | 27.8% | ||
| ≤ 50 | 69 | 91.6% | P = .04 | 41.1% | P = .08 |
| Sex | |||||
| Male | 65 | 83.9% | 31.6% | ||
| Female | 54 | 78.2% | P = .8 | 39.9% | P = .6 |
| Sokal risk group | |||||
| Low | 30 | 100% | 45.5% | ||
| Intermediate | 48 | 83.9% | 28.6% | ||
| High | 41 | 66.5% | P = .03 | 34.7% | P = .7 |
| Status at the onset of imatinib therapy | |||||
| Newly diagnosed CP patients | 60 | 77.8% | 30.7% | ||
| Late CP | 59 | 84.6% | P = .4 | 39.1% | P = .3 |
| Additional cytogenetic abnormalities | |||||
| No | 84 | 85.2% | 41.8% | ||
| Yes | 35 | 75% | P = .2 | 21.3% | P = .07 |
| Time from diagnosis to 2G-TKIs, y† | |||||
| ≤ 6 | 59 | 81.1% | 31.8% | ||
| > 6 | 60 | 82.2% | P = .7 | 38.3% | P = .3 |
| Hematologic resistance to imatinib | |||||
| Yes | 31 | 76.7% | 22.5% | ||
| No | 88 | 84.5% | P = .4 | 40.5% | P = .01 |
| Primary cytogenetic resistance to imatinib | |||||
| Yes | 37 | 70.5% | 13.5% | ||
| No | 82 | 87.9% | P = .03 | 46.7% | P = .001 |
| Need of dose reduction of imatinib (< 400 mg twice daily) | |||||
| Yes | 43 | 97.1% | 50.4% | ||
| No | 76 | 77.3% | P = .06 | 30.2% | P = .08 |
| KD mutation | |||||
| Yes | 26 | 89.3% | 39.0% | ||
| No | 93 | 80.2% | P = .2 | 32.9% | P = .9 |